Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.

Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.

PMID:
31431433
2.

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.

Campbell KS, Cohen AD, Pazina T.

Front Immunol. 2018 Nov 5;9:2551. doi: 10.3389/fimmu.2018.02551. eCollection 2018. Review.

3.

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Pazina T, James AM, MacFarlane AW 4th, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS.

Oncoimmunology. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853. eCollection 2017.

4.

Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression.

Pazina T, Shemesh A, Brusilovsky M, Porgador A, Campbell KS.

Front Immunol. 2017 Mar 30;8:369. doi: 10.3389/fimmu.2017.00369. eCollection 2017. Review.

5.

Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers.

Lerner MB, D'Souza J, Pazina T, Dailey J, Goldsmith BR, Robinson MK, Johnson AT.

ACS Nano. 2012 Jun 26;6(6):5143-9. doi: 10.1021/nn300819s. Epub 2012 May 17.

Supplemental Content

Loading ...
Support Center